Evonik Industries Valuation

Is 0QDS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QDS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QDS (€17.88) is trading below our estimate of fair value (€41.45)

Significantly Below Fair Value: 0QDS is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QDS?

Key metric: As 0QDS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QDS. This is calculated by dividing 0QDS's market cap by their current earnings.
What is 0QDS's PE Ratio?
PE Ratio35.9x
Earnings€229.00m
Market Cap€8.22b

Price to Earnings Ratio vs Peers

How does 0QDS's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QDS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.2x
CRDA Croda International
29.7x15.1%UK£4.8b
JMAT Johnson Matthey
24x28.4%UK£2.6b
VCT Victrex
24.4x37.8%UK£749.6m
TET Treatt
22.7x15.3%UK£256.6m
0QDS Evonik Industries
35.9x33.1%€8.2b

Price-To-Earnings vs Peers: 0QDS is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the peer average (25.2x).


Price to Earnings Ratio vs Industry

How does 0QDS's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0QDS 35.9xIndustry Avg. 17.1xNo. of Companies11PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QDS is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the European Chemicals industry average (17.1x).


Price to Earnings Ratio vs Fair Ratio

What is 0QDS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QDS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.9x
Fair PE Ratio24.7x

Price-To-Earnings vs Fair Ratio: 0QDS is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the estimated Fair Price-To-Earnings Ratio (24.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QDS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€17.88
€22.48
+25.7%
12.1%€26.00€16.60n/a16
Nov ’25€20.23
€22.96
+13.5%
9.6%€26.00€19.90n/a16
Oct ’25€21.08
€22.49
+6.7%
9.8%€26.00€19.00n/a16
Sep ’25€19.97
€22.46
+12.5%
9.9%€26.00€19.00n/a16
Aug ’25€19.10
€22.46
+17.6%
9.8%€26.00€19.00n/a16
Jul ’25€19.03
€21.79
+14.5%
10.6%€25.00€17.50n/a17
Jun ’25€20.13
€21.84
+8.5%
10.7%€25.00€17.50n/a18
May ’25€19.54
€20.70
+5.9%
13.0%€25.00€17.00n/a18
Apr ’25€18.33
€20.22
+10.3%
14.3%€25.00€17.00n/a18
Mar ’25€17.15
€20.28
+18.2%
14.8%€25.00€16.00n/a18
Feb ’25€17.05
€20.28
+18.9%
14.8%€25.00€16.00n/a18
Jan ’25€18.50
€20.49
+10.8%
15.4%€26.00€16.00n/a18
Dec ’24€17.25
€20.64
+19.6%
15.4%€26.00€16.00n/a17
Nov ’24€17.35
€20.28
+16.9%
15.4%€26.00€16.50€20.2318
Oct ’24€17.33
€20.56
+18.6%
15.5%€26.00€16.50€21.0818
Sep ’24€17.78
€20.32
+14.3%
16.3%€26.00€15.00€19.9719
Aug ’24€18.74
€20.55
+9.7%
15.3%€26.00€15.00€19.1019
Jul ’24€17.21
€21.82
+26.8%
16.3%€29.00€15.00€19.0320
Jun ’24€17.70
€22.59
+27.6%
16.1%€29.00€15.00€20.1320
May ’24€19.26
€23.28
+20.9%
18.1%€31.00€15.00€19.5420
Apr ’24€19.27
€23.43
+21.6%
18.2%€31.00€15.00€18.3320
Mar ’24€20.35
€23.44
+15.1%
18.9%€30.00€15.00€17.1520
Feb ’24€20.54
€23.49
+14.4%
18.1%€30.00€15.00€17.0520
Jan ’24€17.95
€24.04
+33.9%
19.5%€34.00€15.00€18.5020
Dec ’23€18.64
€24.45
+31.1%
18.7%€34.00€16.50€17.2520
Nov ’23€18.75
€24.92
+32.8%
20.6%€36.00€16.50€17.3520

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies